Shattuck Labs

pivot change turnaround direction walk away
Biotech

Shattuck axes CD47 program, cuts 40% of staff over weak data

After seeing a “modest” effect on survival, the biotech axed its candidate, pivoted to a preclinical program and gave 40% of its employees pink slips.
Nick Paul Taylor Oct 1, 2024 8:22am
pay deal hand over cash licensing transaction money

Ono taps Shattuck for $227M bifunctional fusion protein deal

Feb 13, 2024 8:29am
Unlocked Money

Takeda-partnered Shattuck nabs a mighty $118M funding round

Jun 15, 2020 8:35am
Takeda building

Takeda taps Texas startup for cancer immunotherapies

Aug 11, 2017 8:56am